02/28/2026
To most, Cystic Fibrosis is a medical statistic. To Amanda and Andrew Jamison, it’s the daily reality of their daughter, Finley.
Finley is pure joy. She’s sassy, she’s a gymnast, and she’s the funniest toddler in the room. But behind the smiles is a "daily reality" that never takes a day off:
⏩ Over 40 pills every single day.
⏩ A feeding pump that runs while she sleeps to support her growth.
⏩ Hours of airway clearance and nebulizer treatments to protect her lungs.
⏩ Up to 6 medical appointments every week.
"I’ll never let it steal her joy or define her childhood," Amanda, Finley’s mom, says. But as she and Andrew know all too well, while breakthroughs like modulators have been life-changing, they are not yet a cure.
This is why CincyTech exists. Our mission is to transform high-potential ideas—across technology and life sciences—into world-class companies. We fund the complex technologies that bridge the gap between a laboratory breakthrough and a child’s life.
We are proud to back Clarametyx Biosciences, a company attacking the challenges that persist for the 1 in 10 Americans living with a rare disease.
Clarametyx is developing CMTX-101, a "biofilm-disrupting" technology that targets the protective shield bacteria use to hide in the lungs.
By funding this science, we aim to help strip away those barriers, giving people like Finley and her parents the hope of better breathing for more time.
𝐓𝐨𝐝𝐚𝐲 𝐢𝐬 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐚𝐲.
With more than 95% of rare diseases still lacking an FDA-approved treatment, the urgency for innovation has never been greater.
We invite you to with us to help spread awareness for the 30 million Americans living with a rare disease.
We fund the science so Finley can focus on being a kid.
How are you showing your stripes today?
